NGM BIOPHARMACEUTICALS INC Deferred Revenue Recognized
NGM BIOPHARMACEUTICALS INC reported Deferred Revenue Recognized of $4.87 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-15.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2021-03-15
- NGM BIOPHARMACEUTICALS INC contract with customer, liability, revenue recognized for the quarter ending 2020-03-31 was $4.87M, a 31.21% decline year-over-year.
- NGM BIOPHARMACEUTICALS INC contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was $7.08M.
- NGM BIOPHARMACEUTICALS INC contract with customer, liability, revenue recognized for fiscal 2020 was $4.87M, a 79.91% decline from fiscal 2019.
- NGM BIOPHARMACEUTICALS INC contract with customer, liability, revenue recognized for fiscal 2019 was $24.25M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.87M 10-K · filed 2021-03-15 | |||
| 2020-09-30 | $4.87M 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $4.87M 10-Q · filed 2020-08-12 | |||
| 2020-03-31 | $4.87M 10-Q · filed 2020-05-13 | |||
| 2019-12-31 | $24.25M 10-K · filed 2021-03-15 | |||
| 2019-09-30 | $16.84M 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $11.68M 10-Q · filed 2019-08-12 | |||
| 2019-03-31 | $7.08M 10-Q · filed 2019-05-16 |